Aptevo Therapeutics Inc. (NASDAQ:APVO) Stock Short Interest Climbs 59.0%

Aptevo Therapeutics Inc. (NASDAQ:APVO) was the recipient of a large growth in short interest in the month of September. As of September 15th, there was short interest totaling 187,942 shares, a growth of 59.0% from the August 31st total of 118,188 shares. Based on an average daily volume of 336,643 shares, the short-interest ratio is presently 0.6 days. Currently, 10.4% of the company’s stock are sold short.

Aptevo Therapeutics Price Performance

APVO opened at $1.76 on Friday. The business’s 50-day moving average is $2.70 and its two-hundred day moving average is $3.98. Aptevo Therapeutics has a 1 year low of $1.37 and a 1 year high of $35.64. The firm has a market capitalization of $3.19 million, a PE ratio of -0.03 and a beta of 1.67.

Aptevo Therapeutics (NASDAQ:APVO) last released its quarterly earnings results on Friday, August 14th. The biotechnology company reported ($5.31) EPS for the quarter, beating the consensus estimate of ($6.02) by $0.71. As a group, sell-side analysts expect that Aptevo Therapeutics will post -17.04 EPS for the current year.

Analysts Set New Price Targets

Separately, Weiss Ratings lowered shares of Aptevo Therapeutics from a “sell (e+)” rating to a “sell (e)” rating in a report on Friday, September 25th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Aptevo Therapeutics currently has a consensus rating of “Sell”.

About Aptevo Therapeutics

Aptevo Therapeutics Inc (NASDAQ:APVO) is a biotechnology company focused on developing targeted immunotherapies for cancer and other serious diseases. The company’s research programs are designed to engage the immune system and direct it against specific disease-related cells or targets.

Aptevo’s pipeline is based primarily on its ADAPTIR and ADAPTIR-FLEX platform technologies, which support the development of engineered, multispecific antibodies. These programs have included investigational candidates such as APVO436, an immune-cell engager being studied in hematologic malignancies, and other compounds aimed at treating solid tumors and blood cancers.